At a glance
- CagriSema is not an FDA-approved drug: Drugs@FDA has no record of it.
- PubMed lists 82 publications mentioning it, including 13 randomized controlled trials and 3 animal-only studies.
- ClinicalTrials.gov lists 35 registered studies testing it (13 active).
- FDA's adverse event system (FAERS) holds 2 reports mentioning it; 1 classified as serious. Reports do not prove causation.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Components
This is a vendor blend. Data for the blend itself only counts records that mention every component together; each component has its own page.
Regulatory status
Drugs@FDA applications
No application found in Drugs@FDA, FDA's database of approved drugs.
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.
Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Latest publications
- Continued CagriSema treatment preserves weight loss by reducing energy intake and maintaining energy expenditure in rats.
- Efficacy and Safety of CagriSema in Type 2 Diabetes: A Dose- and Comparator-Specific Systematic Review and Bayesian Meta-Analysis.
- CagriSema versus Semaglutide 2.4 mg monotherapy for weight management in adults with overweight or obesity, with or without type 2 diabetes: a systematic review, meta-analysis, and trial sequential analysis.
- Design and baseline characteristics of the CagriSema cardiovascular outcomes trial (REDEFINE 3).
- Recent Studies on the Effectiveness and Safety of Anti-Obesity Medications: A Scoping Review.
- Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents.
- New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus.
- Efficacy and Safety of CagriSema for Metabolic Outcomes: Systematic Review and Pairwise Meta-Analysis of Randomized Controlled Trials.
- Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats.
- Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials.
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
- Registered
- 35
- Active
- 13
- With posted results
- 1
Conditions studied
Show 25 more studies
All 35 studies on ClinicalTrials.gov ↗
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
- Reports
- 2
- Serious
- 1
- With death outcome
- 0
Most reported reactions
Adverse event reports do not prove that the substance caused these effects. Side effects not listed here may still occur. Reaction terms are MedDRA terms as reported to FAERS.
Source: FDA FAERS (FAERS data as of July 30, 2026) · verified October 30, 2026 · API query
Change history
No changes since monitoring began on October 30, 2026.